O	0	8	Efficacy
O	9	12	and
O	13	25	tolerability
O	26	28	of
B-intervention	29	39	aprepitant
O	40	43	for
O	44	47	the
O	48	58	prevention
O	59	61	of
B-condition	62	74	chemotherapy
I-condition	74	75	-
I-condition	75	82	induced
I-condition	83	89	nausea
I-condition	90	93	and
I-condition	94	102	vomiting
O	103	105	in
O	106	114	patients
O	115	119	with
O	120	126	breast
O	127	133	cancer
O	134	139	after
O	140	150	moderately
O	151	161	emetogenic
O	162	174	chemotherapy
O	174	175	.

O	176	180	This
O	181	183	is
O	184	187	the
O	188	193	first
O	194	199	study
O	200	202	in
O	203	208	which
O	209	212	the
O	213	215	NK
O	215	216	(
O	216	217	1
O	217	218	)
O	218	219	-
O	219	227	receptor
O	228	238	antagonist
O	238	239	,
O	240	250	aprepitant
O	251	252	(
O	252	255	APR
O	255	256	)
O	256	257	,
O	258	261	was
O	262	271	evaluated
O	272	275	for
O	276	279	the
O	280	290	prevention
O	291	293	of
O	294	306	chemotherapy
O	306	307	-
O	307	314	induced
O	315	321	nausea
O	322	325	and
O	326	334	vomiting
O	335	336	(
O	336	340	CINV
O	340	341	)
O	342	346	with
O	347	357	moderately
O	358	368	emetogenic
O	369	381	chemotherapy
O	381	382	.

O	383	391	Eligible
B-eligibility	392	398	breast
I-eligibility	399	405	cancer
I-eligibility	406	414	patients
I-eligibility	415	419	were
I-eligibility	420	425	naive
I-eligibility	426	428	to
I-eligibility	429	439	emetogenic
I-eligibility	440	452	chemotherapy
I-eligibility	453	456	and
I-eligibility	457	464	treated
I-eligibility	465	469	with
I-eligibility	470	486	cyclophosphamide
I-eligibility	487	488	+
I-eligibility	488	489	/
I-eligibility	489	490	-
I-eligibility	491	502	doxorubicin
I-eligibility	503	505	or
I-eligibility	506	516	epirubicin
O	516	517	.

O	518	526	Patients
O	527	531	were
O	532	540	randomly
O	541	549	assigned
O	550	552	to
O	553	559	either
O	560	562	an
O	563	573	aprepitant
O	574	581	regimen
O	582	583	(
O	583	586	day
O	587	588	1
O	588	589	,
O	590	593	APR
O	594	597	125
O	598	600	mg
O	600	601	,
O	602	613	ondansetron
O	614	615	(
O	615	618	OND
O	618	619	)
O	620	621	8
O	622	624	mg
O	624	625	,
O	626	629	and
O	630	643	dexamethasone
O	644	646	12
O	647	649	mg
O	650	656	before
O	657	669	chemotherapy
O	670	673	and
O	674	677	OND
O	678	679	8
O	680	682	mg
O	683	684	8
O	685	690	hours
O	691	696	later
O	696	697	;
O	698	702	days
O	703	704	2
O	705	712	through
O	713	714	3
O	714	715	,
O	716	719	APR
O	720	722	80
O	723	725	qd
O	725	726	)
O	727	728	[
O	728	734	DOSAGE
O	735	740	ERROR
O	741	750	CORRECTED
O	750	751	]
O	752	754	or
O	755	756	a
B-control	757	764	control
I-control	765	772	regimen
O	773	774	(
O	774	777	day
O	778	779	1
O	779	780	,
O	781	784	OND
O	785	786	8
O	787	789	mg
O	790	793	and
O	794	807	dexamethasone
O	808	810	20
O	811	813	mg
O	814	820	before
O	821	833	chemotherapy
O	834	837	and
O	838	841	OND
O	842	843	8
O	844	846	mg
O	847	848	8
O	849	854	hours
O	855	860	later
O	860	861	;
O	862	866	days
O	867	868	2
O	869	876	through
O	877	878	3
O	878	879	,
O	880	883	OND
O	884	885	8
O	886	888	mg
O	889	892	bid
O	892	893	)
O	893	894	.

O	895	899	Data
O	900	902	on
O	903	909	nausea
O	909	910	,
O	911	919	vomiting
O	919	920	,
O	921	924	and
O	925	928	use
O	929	931	of
O	932	938	rescue
O	939	949	medication
O	950	954	were
O	955	964	collected
O	965	969	with
O	970	971	a
O	972	976	self
O	976	977	-
O	977	983	report
O	984	989	diary
O	989	990	.

O	991	994	The
O	995	1002	primary
O	1003	1011	efficacy
O	1012	1015	end
O	1016	1021	point
O	1022	1025	was
O	1026	1029	the
B-outcome-Measure	1030	1040	proportion
I-outcome-Measure	1041	1043	of
I-outcome-Measure	1044	1052	patients
I-outcome-Measure	1053	1057	with
I-outcome-Measure	1058	1066	complete
I-outcome-Measure	1067	1075	response
O	1075	1076	,
O	1077	1084	defined
O	1085	1087	as
O	1088	1090	no
O	1091	1099	vomiting
O	1100	1103	and
O	1104	1106	no
O	1107	1110	use
O	1111	1113	of
O	1114	1120	rescue
O	1121	1128	therapy
O	1128	1129	,
O	1130	1136	during
O	1137	1140	120
O	1141	1146	hours
O	1147	1152	after
O	1153	1163	initiation
O	1164	1166	of
O	1167	1179	chemotherapy
O	1180	1182	in
O	1183	1188	cycle
O	1189	1190	1
O	1190	1191	.

O	1192	1195	The
O	1196	1205	secondary
O	1206	1209	end
O	1210	1215	point
O	1216	1219	was
O	1220	1223	the
B-outcome-Measure	1224	1234	proportion
I-outcome-Measure	1235	1237	of
I-outcome-Measure	1238	1246	patients
I-outcome-Measure	1247	1251	with
I-outcome-Measure	1252	1254	an
I-outcome-Measure	1255	1262	average
I-outcome-Measure	1263	1267	item
I-outcome-Measure	1268	1273	score
I-outcome-Measure	1274	1280	higher
I-outcome-Measure	1281	1285	than
I-outcome-Measure	1286	1287	6
I-outcome-Measure	1288	1290	of
I-outcome-Measure	1291	1292	7
I-outcome-Measure	1293	1295	on
I-outcome-Measure	1296	1299	the
I-outcome-Measure	1300	1310	Functional
I-outcome-Measure	1311	1317	Living
I-outcome-Measure	1318	1323	Index
I-outcome-Measure	1323	1324	-
I-outcome-Measure	1324	1330	Emesis
I-outcome-Measure	1331	1344	questionnaire
O	1344	1345	.

O	1346	1348	Of
B-total-participants	1349	1352	866
O	1353	1361	patients
O	1362	1372	randomized
O	1372	1373	,
B-total-participants	1374	1377	857
O	1378	1386	patients
O	1387	1388	(
O	1388	1390	99
O	1390	1391	%
O	1391	1392	)
O	1393	1397	were
O	1398	1408	assessable
O	1408	1409	.

O	1410	1417	Overall
B-outcome	1418	1426	complete
I-outcome	1427	1435	response
O	1436	1439	was
O	1440	1447	greater
O	1448	1452	with
O	1453	1456	the
O	1457	1467	aprepitant
O	1468	1475	regimen
O	1476	1480	than
O	1481	1485	with
O	1486	1489	the
O	1490	1497	control
O	1498	1505	regimen
O	1506	1507	(
B-iv-bin-percent	1507	1509	50
I-iv-bin-percent	1509	1510	.
I-iv-bin-percent	1510	1511	8
I-iv-bin-percent	1511	1512	%
O	1513	1514	v
B-cv-bin-percent	1515	1517	42
I-cv-bin-percent	1517	1518	.
I-cv-bin-percent	1518	1519	5
I-cv-bin-percent	1519	1520	%
O	1520	1521	;
O	1522	1523	P
O	1524	1525	=
O	1526	1527	.
O	1527	1530	015
O	1530	1531	)
O	1531	1532	.

O	1533	1537	More
O	1538	1546	patients
O	1547	1549	in
O	1550	1553	the
O	1554	1564	aprepitant
O	1565	1570	group
O	1571	1579	reported
O	1580	1587	minimal
O	1588	1590	or
O	1591	1593	no
B-outcome	1594	1600	impact
I-outcome	1601	1603	of
I-outcome	1604	1608	CINV
I-outcome	1609	1611	on
I-outcome	1612	1617	daily
I-outcome	1618	1622	life
O	1623	1624	(
B-iv-bin-percent	1624	1626	63
I-iv-bin-percent	1626	1627	.
I-iv-bin-percent	1627	1628	5
I-iv-bin-percent	1628	1629	%
O	1630	1631	v
B-cv-bin-percent	1632	1634	55
I-cv-bin-percent	1634	1635	.
I-cv-bin-percent	1635	1636	6
I-cv-bin-percent	1636	1637	%
O	1637	1638	;
O	1639	1640	P
O	1641	1642	=
O	1643	1644	.
O	1644	1647	019
O	1647	1648	)
O	1648	1649	.

O	1650	1654	Both
O	1655	1665	treatments
O	1666	1670	were
O	1671	1680	generally
B-outcome	1681	1685	well
I-outcome	1686	1695	tolerated
O	1695	1696	.

O	1697	1700	The
O	1701	1711	aprepitant
O	1712	1719	regimen
O	1720	1723	was
O	1724	1728	more
O	1729	1738	effective
O	1739	1743	than
O	1744	1747	the
O	1748	1755	control
O	1756	1763	regimen
O	1764	1767	for
O	1768	1778	prevention
O	1779	1781	of
O	1782	1786	CINV
O	1787	1789	in
O	1790	1798	patients
O	1799	1808	receiving
O	1809	1813	both
O	1814	1816	an
O	1817	1830	anthracycline
O	1831	1834	and
O	1835	1851	cyclophosphamide
O	1851	1852	.
